Intervacc AB Logo

Intervacc AB

Develops recombinant protein-based vaccines for animal health.

IVACC | ST

Overview

Corporate Details

ISIN(s):
SE0009607252 (+1 more)
LEI:
549300OICIVZBBZRNZ64
Country:
Sweden
Address:
Västertorpsvägen 135B, 129 44 Hägersten

Description

Intervacc AB is a biotechnology company focused on developing a new generation of vaccines for animal health. The company's technology platform utilizes fusions of recombinant proteins, a modern approach that avoids attenuated live strains, based on research from the Karolinska Institutet and the Swedish University of Agricultural Sciences. Its lead commercial product is Strangvac®, a vaccine for horses against strangles caused by Streptococcus equi. The development pipeline includes vaccine candidates targeting significant bacterial diseases, such as Streptococcus suis infections in pigs and Staphylococcus aureus-induced mastitis in dairy cows. Intervacc's mission is to improve animal health and welfare while contributing to the reduction of antibiotic use and combating antimicrobial resistance. The company manages sales and distribution through its subsidiary, Nordvacc.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Intervacc AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Intervacc AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Intervacc AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-26 Lennart Johansson Other Other 813,474 691,452.90 SEK
2025-02-21 Lennart Johansson Other Other 324,156 275,532.60 SEK

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.